Pfizer's oncology unit displays mixed Q1 trends as key drugs and biosimilars offset Ibrance declines ahead of earnings on May 5 ...

U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk.

Pfizer is ramping up its fight to keep Danish drugmaker Novo Nordisk from spoiling its acquisition of an anti-obesity biotech, launching a legal campaign that paints Novo as an interfering European ...

NEW YORK (AP) — U.S. pharmaceutical giant Pfizer signed a deal to purchase development-stage obesity drugmaker Metsera Inc., winning a bidding war against Novo Nordisk, the Danish drugmaker behind ...

U.S. pharmaceutical giant Pfizer signed a deal to purchase development-stage obesity drugmaker Metsera Inc., winning a bidding war against Novo Nordisk, the Danish drugmaker behind weight-loss ...

For the past 7 years, pharmaceuticals that work as glucagon-like peptide 1 (GLP-1) receptor agonists have dominated the weight-loss and diabetes markets. These drugs, currently so ...

Add Yahoo as a preferred source to see more of our stories on Google. Albert Bourla, chairman and chief executive officer of the pharmaceutical company Pfizer. speaks in the Oval Office of the White ...

WASHINGTON -- Pfizer has agreed to lower the cost of prescription drugs for Medicaid under a deal struck with the Trump administration, President Donald Trump said Tuesday as he promised similar deals ...

The pharmaceutical company updated its sales guidance for 2025, saying it now expects $62 billion in revenue for the year Pfizer revised its revenue expectations for 2025 and detailed its outlook for ...